T2 Biosystems, 286 Cardinal Medeiros Ave, Cambridge, MA 02141, US

Beacon Therapeutics is an ophthalmic gene therapy company based in Cambridge, MA. They are dedicated to saving and restoring the vision of patients with a wide range of prevalent and rare retinal diseases that lead to blindness. Their pioneering ocular gene therapy approach involves modifying a patient's cells by adding a functional copy of the mutated gene responsible for the disease, allowing the body to produce proteins to treat or prevent genetic conditions. With a focus on diseases such as X-Linked Retinitis Pigmentosa, Dry Age-related Macular Degeneration, and Cone Rod Dystrophy, Beacon Therapeutics aims to provide long-lasting benefits and improve the quality of life for patients. Through their bold science and ongoing clinical trials, Beacon Therapeutics offers a real hope for lasting treatments for severe forms of genetic blindness. Their innovative gene therapy approach has shown significant gains in vision in recent studies, providing a glimmer of hope for those affected by these devastating eye diseases. With a commitment to transforming lives and making remarkable happen, Beacon Therapeutics is at the forefront of ocular gene therapy, working towards a future where blindness can be prevented or treated effectively.Generated from the website

Seventh Sense Bio

Optikos Corporation

Bright Horizons

Bright Horizons at Kendall Square